

# Experimental Plan

Callum Malcolm

2023-12-07

## Contents

<b>Project 1: Modelling the BL Tumour Microenviroment</b>	<b>2</b>
Overview . . . . .	2
Background . . . . .	2
Experimental Plan . . . . .	2
E1: NSG vs BALB/C A20 injection . . . . .	2

# Project 1: Modelling the BL Tumour Microenvironment

## Overview

- Using A20 to model BL immune TME
  - Look specifically at T-cell infiltration
  - Immune evasion mechanisms deployed by BL
- Compare results to patient data
- Apply findings to humanised mouse models of BL PDX

## Background

- The impact of immune TME in BL is unclear
- BL

## Experimental Plan

### E1: NSG vs BALB/C A20 injection

#### E1 Overview

- Compare between immunocompetent and immunocompromised mice
- Basic actors to compare
  - Tumour growth rate
  - Tumour size

## IHC Panel

- Compare markers between tumour types
- Burkitt IHC identification:
  - CD10+ (B-Cell Germinal Centre)
  - Bcl-2-
  - Ki-67%hi (proliferation index)

Potential IHC Panel Markers

Cell Type	Marker
Proliferation marker	Ki67
B cell	CD20
T cells (all)	CD3
T Cells (cytotoxic)	CD8
T cells (helper)	CD 4
Dendritic Cells	CD11c
Macrophage	F4/80

## Flow Panel

- Options are:
  - Standard T Cell
  - TRegs
  - B-cells
  - DC Mono CD11c
  - Th17
  - Tfh

Standard T Cell

Cell Type	Marker
T Memory	CXCR3
Naive Immune Cells	CCR7
Naive T Cells	CD45RA
Th17	CCR6
GC B-Cells	CD38
TRegs (Helper)	CD4
Macrophage	HLA-DR
T Cells (all)	CD3
T Cells (Cytotoxic)	CD8